Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
September 2023
in “
Dermatology and therapy
”
TLDR Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
The document summarizes a post hoc analysis of the ALLEGRO phase 2b/3 trial involving 655 patients with alopecia areata (AA), which aimed to identify hair loss profiles and assess the efficacy of ritlecitinib, an oral JAK3 and TEC family kinase inhibitor. The study identified five distinct hair loss profiles and found that ritlecitinib was significantly more effective than placebo in improving hair growth and patient satisfaction after 24 weeks of treatment, regardless of the patient's baseline hair loss profile. The efficacy was measured by the Patient Global Impression of Change (PGI-C) and Patient Satisfaction with Hair Growth (P-Sat), with higher odds ratios for positive responses in the ritlecitinib groups compared to placebo. The study, sponsored by Pfizer Inc., suggests ritlecitinib is an effective treatment for AA across different hair loss profiles, although it acknowledges the limitation of the 24-week study duration.